HIGHLIGHTS

First program to treat a patient with Kite’s TECARTUS™ CAR T-cell Therapy

Montefiore Einstein Cancer Center’s Hematologic Malignancy Program was selected to be the first of its kind in the United States to treat relapsed or refractory mantle cell lymphoma using the innovative new therapy.

Montefiore Einstein Cancer Center is among a select group of centers nationwide that have been approved as authorized Kite TECARTUS™ treatment sites. Based on their proven expertise in cellular therapy and leadership in CAR T-cell therapy, our Hematologic Malignancy and Transplant team were chosen as the first to treat a patient using TECARTUS™ CAR T-cell therapy. Ira Braunschweig, MD, Director of the Stem Cell Transplant Program and Clinical Program Director of Hematologic Malignancies, served as principal investigator for the ongoing ZUMA-1 study, which tested CAR T-cell therapy for relapsed refractory lymphoma and established CAR T-cell therapy as the standard of care for patients where other standard therapies have failed. 

 

Patient referrals

At Montefiore Einstein Cancer Center, we know providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.

Contact us

Anne McDarby
Associate Director, Network Program Management
Montefiore Einstein Cancer Center

1-718-862-8840 /ext. 460
amcdarby@montefiore.org

Montefiore Einstein Cancer Center
Montefiore.org
Einsteinmed.edu